Company profile
ELEDON PHARMACEUTICALS, INC.
NASDAQ:ELDNBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| TEGOPRUBART | phase3 | — | 5 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06126380 | phase2 | enrolling_by_invitation | 2023-10-25 | 2029-12-01 | Eledon Pharmaceuticals | Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients |
| NCT05125068 | phase2 | terminated | 2022-03-21 | 2023-07-31 | Eledon Pharmaceuticals | Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN) |
| NCT05983770 | phase2 | completed | 2023-08-30 | 2025-09-11 | Eledon Pharmaceuticals | Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation |
| NCT05027906 | phase1_2 | recruiting | 2022-02-18 | 2027-01-01 | Eledon Pharmaceuticals | Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant |
| NCT05480657 | phase1_2 | withdrawn | 2022-09-30 | 2024-08-01 | Eledon Pharmaceuticals | Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D |
FDA applications (0)
No records yet.